AQST Keith J Kendall sells $255K worth of shares
Jan 03, 2026, 11:42 AM
0.00%
What does AQST do
Aquestive Therapeutics, headquartered in Warren, New Jersey, develops differentiated pharmaceutical products for unmet medical needs, including severe allergic reactions and CNS diseases, using its proprietary PharmFilm technology. The company's portfolio includes Anaphylm and Libervant, with an IPO launched on July 25, 2018.
Keith J Kendall sold 50,000 shares of AQST on 4 June at $5.11 per share, worth a total of $255K. They now own 638,964 AQST shares, or a 7% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.